Shanghai's Phagelux Raises $10 Million for Anti-Bacterial Phages

Phagelux, a Shanghai anti-bacterial company, announced a $10 million funding from existing and new institutional investors. The company is developing anti-bacterial products for human and agricultural health using phage and phage-based technologies. Phages are potential alternatives to many uses of antibiotics, including drug-resistant bacteria strains. Phagelux said it is close to commercialization of its first marketed products. More details.... Share this with colleagues: // //